These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15464913)

  • 41. Peptide vaccine therapy for leukemia.
    Rezvani K
    Int J Hematol; 2011 Mar; 93(3):274-280. PubMed ID: 21380929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rekindling cancer vaccines.
    Branca MA
    Nat Biotechnol; 2016 Oct; 34(10):1019-1024. PubMed ID: 27727216
    [No Abstract]   [Full Text] [Related]  

  • 44. [Immunotherapy].
    Yasukawa M
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():230-5. PubMed ID: 23133959
    [No Abstract]   [Full Text] [Related]  

  • 45. [Cancer vaccine with peptides derived from tumor rejection antigens].
    Niiya F; Mine T; Toh U; Yamana H; Itoh K
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():438-42. PubMed ID: 11424421
    [No Abstract]   [Full Text] [Related]  

  • 46. Breast cancer vaccines: promise for the future or pipe dream?
    Mittendorf EA; Peoples GE; Singletary SE
    Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulation against leukemias and lymphomas: a realistic future treatment?
    Mittal S; Marshall NA; Barker RN; Vickers MA
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):101-8. PubMed ID: 17719232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccines in lymphoma.
    Levy R
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
    Spisek R
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
    [No Abstract]   [Full Text] [Related]  

  • 50. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.
    Brichard VG; Lejeune D
    Vaccine; 2007 Sep; 25 Suppl 2():B61-71. PubMed ID: 17916463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [PRAME protein expressed in leukemia cells as a target molecule for immunotherapy].
    Ikeda H; Matsushita M; Kawakami H
    Rinsho Ketsueki; 1999 Jun; 40(6):484-6. PubMed ID: 10422284
    [No Abstract]   [Full Text] [Related]  

  • 52. Tumor vaccine: current trends in antigen specific immunotherapy.
    Baral R
    Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current status of vaccination therapy for leukemias.
    Reichardt VL; Brossart P
    Curr Hematol Rep; 2005 Jan; 4(1):73-6. PubMed ID: 15610663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antitumour vaccination in patients with ENT tumours. Successful track record].
    Dyckhoff G; Herold-Mende C
    HNO; 2005 Mar; 53(3):209-12. PubMed ID: 15726304
    [No Abstract]   [Full Text] [Related]  

  • 56. Chromosomal aberrations in leukaemia cells may delete tumour target antigens of stem cell-based immunotherapy.
    Hambach L; Nijmeijer BA; Drabbels JJ; Falkenburg JH; Goulmy E
    Leukemia; 2006 Jul; 20(7):1298-300. PubMed ID: 16628185
    [No Abstract]   [Full Text] [Related]  

  • 57. The reverse proteomics for identification of tumor antigens.
    Lee SY; Jeoung D
    J Microbiol Biotechnol; 2007 Jun; 17(6):879-90. PubMed ID: 18050904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage.
    Hodi FS
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):673-8. PubMed ID: 16467076
    [No Abstract]   [Full Text] [Related]  

  • 60. [Cancer vaccines].
    Kyte JA
    Tidsskr Nor Laegeforen; 2006 Nov; 126(22):2969-73. PubMed ID: 17117197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.